As pharma companies aim to overcome development obstacles, it is essential to implement GMP-compliance to ensure quality and safety. Incorporating GMP expertise alongside novel technologies, such as nanoparticle engineering, that can enhance the properties of APIs and dosage forms holds promise for viable clinical and commercial success.
By reducing the size of drug particles, nanoforming can open up exciting new opportunities, from increasing bioavailability to enabling sustained drug delivery. Discover the benefits for both patients and the planet through the Nanoform toolbox, supported by data from relevant case studies.
As more companies opt for the benefits presented by lower dosage forms, demand for high-potency active pharmaceutical ingredients (HPAPIs) is rising. Accessing specialized facilities with HPAPI handling capabilities is crucial to ensure the safe development and manufacturing of these drug substances.
Alzheimer's disease accounts for 60 to 80% of dementia cases. Commercial insights officer Jamie Unwin discusses the power of Nanoform's innovative nanoparticle engineering technology and AI-based digital twin.
